Friday, December 2, 2011

Less phosphorous, less calcification

A study from the November issue of American Journal of Clinical Nutrition explored how serum phosphorus concentrations are associated with an increased risk of cardiovascular disease (CVD) and mortality in patients with renal insufficiency. However, it is unclear whether this correlation occurs in individuals without renal insufficiency. The researchers investigated Korean subjects, who usually ingest less phosphorus than do Western individuals. As suspected, a lower concentration of serum phosphorus within the normal range was found, and could be associated with less calcification of the coronary artery in Koreans with normal renal function.

Wednesday, November 23, 2011

Gorge on grains at 4, overweight at 6.

A Journal Nutrition study examined dietary factors associated with overweight in a population-based sample of 6-y-old children. Dietary intake was examined from 1014 children at 4 y of age. Weight and height were measured using a standard protocol at 6 y. Higher daily energy intake at 4 y was significantly related to overweight at 6 y.Boys who consumed more than 5 servings of grain products per day at 4 y were more likely to be overweight at 6 y compared to those who did not. The findings provide support for the revisions made in the Canadian dietary guidelines for young children, which now recommend 4–7 servings of grain products daily for children aged 4–8 y rather than the excessive 5–12 servings of previous recommendations.

Bonnie - and 4-7 servings is still way too much!

Tuesday, November 22, 2011

Vitamin C deficiency associated with inflammation

Heart failure patients who don't eat enough vitamin C-rich foods have higher levels of inflammation and a higher risk of cardiac complications and death. This is the first study to demonstrate that low vitamin C intake is associated with worse outcomes in heart failure patients. Low levels of vitamin C were associated with higher levels of high sensitivity C-Reactive protein (hsCRP) and shorter intervals without major cardiac issues or death for heart failure patients, in research presented at the American Heart Association's Scientific Sessions 2011. Compared to those with high vitamin C intake from food, heart failure patients in the study who had low vitamin C intake were 2.4 times more likely to have higher levels of hsCRP, a marker for inflammation and a risk factor for heart disease.

Monday, November 21, 2011

Osteoporosis Update

A new study in Rheumatology exhibits timeline, as well as cautionary tale, concerning the etiology and treatment of chronic diseases. In this instance, osteoporosis, a disease characterized by low bone strength and fractures that occur with very low-impact loads, has experienced many changes over the past 20 years and we should expect to see many more in the future.

Prior to 1990, there was little activity in the field: although there were some small studies with sodium fluoride, they set the field back because these compounds improved bone mass but increased bone fragility and fractures. While osteoporosis, or bone fragility, was generally accepted to be part of the normal process of aging in post-menopausal women, an osteoporotic fracture diagnosed the disease, unfortunately at a very advanced stage. Until the development of DPA followed by dual-energy X-ray absorptiometry (DEXA), there was no method to determine an individual's risk of an osteoporotic fracture before the event. However, in 1992, T-scores became a way to identify individuals who would, over time, be at increased risk of osteoporotic fractures. This ability to identify individuals at risk for fractures prior to their occurrence by DEXA, coupled in 1990 with the first studies to find a reduction in incident vertebral fractures with the bisphosphonate etidronate, administered for 2 weeks every 3 months, followed by the approval of the bisphosphonate alendronate in the USA in 1995, really jump-started the field. Post- and pre-menopausal women and men obtained BMD scans, and, based on a T-score of −1 or below at the lumbar spine or hip, were started on this anti-resorptive agent indefinitely. Over time, other bisphosphonates were approved, initially daily treatment, then weekly, then monthly, followed by i.v. therapies, first every 3 months and now annually.

The past decade also saw the approval of the first 'anabolic' or bone-building agent that could increase bone strength by increasing both bone formation and bone resorption. The anabolic agent teriparatide allowed bone strength to increase by adding bone to existing trabeculae. However, with the discontinuation of teriparatide, the new bone would be rapidly lost; the addition of an anti-resorptive agent maintained or even increased BMD.

In addition, the Women's Health Initiative Study reported that HRT, while effective in reducing hip fractures and gastrointestinal cancer, had risks of cardiovascular events that outweighed the benefits. This dramatically changed how physicians treated post-menopausal women, especially in the prevention of estrogen-deficient bone loss in early menopause. However, the number of new, generally non-hormonal medications to treat or prevent osteoporosis kept clinicians busy learning the biology of bone metabolism, and most became very good at identifying and prescribing for patients who should be treated for osteoporosis.

One drug company-sponsored study suggested to clinicians that after 5 years an anti-resorptive agent could be discontinued, but no guidelines were produced on how to monitor these subjects after therapy was discontinued: this has been left to clinicians to figure out. In the past 3 years, quite unexpectedly, a number of series of cases of subtrochanteric or atypical fractures have been reported in women treated with bisphosphonates for a number of years. The reports from multiple centers are strikingly similar. The American Society of Bone and Mineral Research convened a task force to investigate the problem and the Food and Drug Administration made recommendations. One of the major risk factors appears to be the length of time a patient has taken the bisphophonate. While pharmaceutical manufacturers were successful in convincing clinicians that these medications would improve patients' bone strength, no guidance was provided on the length of time that the medication should be prescribed. The Phase III studies carried out to seek FDA approval of the bisphosphonates were only 3 years in duration. However, many of the patients' subtrochanteric fractures had been treated with these medications for much longer. So we have learnt a lesson in the treatment of osteoporosis: 3 years is effective, and much longer might cause some harm. This story is not finished...

Bonnie - the effectiveness is highly questionable as it is, but the harm is evident. I have seen it too many times. In addition, the key marker that clinicians use for assessing osteoporosis risk, T-scores, are highly questionable as well.

...The use of the T-score to identify patients who might be at risk for osteoporotic fractures, and using a T-score of −1 or less as a threshold to treat patients with bone-active medications, was not satisfying.

While medications can improve bone strength, a patient generally has to fall to suffer a hip fracture. Clinicians, almost as a reflex, institute medications to treat osteoporosis, and fail to do an assessment of a patient's risk of falling. A thorough evaluation for osteoporosis and fracture risk includes: a review of the patient's medications for sedatives/hypnotics that impair balance and increase fall risk; a physical examination to determine muscle strength and balance; and a review of laboratory tests including hemoglobin, hematocrit and electrolytes. Going forward, the authors of this study would like to believe clinicians will be more thorough in their assessment of fracture risk both with FRAX and an assessment of fall risk, and interventions may be both pharmacological and non-pharmacological. We have come a long way, but we have much left to do.

Bonnie - without saying it, the authors of this study are hinting that osteoporosis is the perfect example of how drug companies concocted a disease in order to open up a new market for themselves. The one prescription medication the authors ignored, which is the cheapest, safest, and has had good success, is salmon calcitonin. Calcitonin works on specifically on bone resorption, not bone formation, which bisphosphonates perform in irregular, brittle fashion. The following study has even more exciting news regarding a new delivery system for calcitonin.

Oral recombinant salmon calcitonin tablets (200 mg daily) are more effective at improving lumbar spine bone mineral density (BMD) after 48 weeks than placebo or a nasal formulation of the hormone, according to the results of a phase 3 multinational double-blind trial presented here at the American Society for Bone and Mineral Research 2011 Annual Meeting. Dual-emission X-ray absorptiometry scans showed the oral formulation to be better than the nasal formulation at increasing BMD of the lumbar spine. At the exit visit, fasting carboxy-terminal collagen crosslink (CTx) serum levels, indicating bone resorption, decreased by 29.9% in the oral groups.

Thursday, November 17, 2011

Turmeric enemas for C. Difficile

Turmeric enemas may be as tolerable and effective as vancomycin enemas for treating Clostridium difficile colitis. Turmeric, a plant belonging to the ginger family, produces a bright yellow spice that has been used for thousands of years in food and as medicine. Curcumin is its major component. Turmeric is known to have antioxidant, anti-inflammatory and anti-microbial properties, and it also slows cell proliferation.

Researchers presenting at the American College of Gastroenterology's annual meeting randomly assigned 36 patients to twice-daily enemas containing either vancomycin (250 mg), turmeric (1 g), or placebo, for 10 days. Patients also took 500 mg metronidazole orally three times a day for two weeks. The infection was eradicated in similar proportions of patients in the vancomycin and turmeric groups (83% and 76%, respectively), compared to 66% in the placebo group. At 21 days after the end of treatment, the ATLAS score for clinical severity was reduced by 60% in the vancomycin and turmeric groups, compared to 38% in the placebo group. In addition, the endoscopic appearance of luminal ulcers was improved with vancomycin and turmeric compared to placebo. Recurrence developed in 10% of patients treated with vancomycin, 9% of those in the turmeric group, and 29% of patients who received the placebo.

"The people who got vancomycin, they did very well, and curcumin, they did equally well. The beauty of it was that the curcumin was much, much less expensive." The researchers estimated the cost of the turmeric enemas at $150 for 14 days of twice-daily enemas.

Causes exacerbating C. Difficile

About 500,000 people in the U.S. become infected with the potentially fatal diarrhea bug Clostridium difficile (C. diff.) each year. A new study sheds light on who is most at risk -- and why.

What's more, the use of antibiotics, acid-suppressing proton pump inhibitors (PPIs), and older age all increase the risk of C. diff infection. Antibiotics and Anti-Reflux Drugs Antibiotics can wipe out bacteria, which can offset the balance between good and bad bacteria in the gut, setting the stage for C. diff infection. PPIs such as Nexium, Prevacid, Prilosec, and Protonix may increase this risk in a different way. Stomach acid is one of the main defenses against bacteria. These drugs suppress acid, which may give bacteria the freedom to run rampant in your gut. "We know the micro-organisms in the gut is a delicate balance of good and bad bacteria, which can be disrupted by many things,"says the authors. This includes the inappropriate or overuse of antibiotics, as well as changing the acidity level of the gastrointestinal tract with acid suppression. "A single dose of antibiotics increases your risk of C. diff by upsetting the flora," the authors say. Antibiotics are not effective in treating a common cold caused by a virus. They are effective against bacterial infections.

PPI overuse may also be partly to blame. "We need to decide if a patient really requires long-term use of PPIs and think about drug holidays in those that do, as well as alternatives to manage the symptoms," authors say. "It is amazing for the frequency with which we see C. diff infection in the hospital and how little we know about the natural history of this infection and this study provides a lot of insight into the process."

Tuesday, November 15, 2011

Nutritional Ratings Systems and Risk of Chronic Disease

If you have not seen them already, expect to see food quality ratings everywhere on your local grocery stores shelves over the next few years. Nutrition IQ, Nutripoints, NuVal, Guiding Stars, and even a Walmart healthy seal are sure to be the most popular system evaluating the quality of our foodstuffs. While one should be optimistic that these systems will be valid and objective, we have our concerns.
  1. Who will monitor conflicts of interest? Do we leave it up the the companies themselves to assure that Big Food will not "payola" the system for preferential quality ratings? Some grocery manufacturers created these systems. We are afraid that they will rig the quality ratings the same way they pay for prime shelf space.
  2. Will these confuse the consumer further? With so many schools of thought on what foods are considered healthy, consumers may be convinced to purchase foods which experts such as ourselves would not consider healthy. For example, just because foods are "low fat" or "sugar-free" means that they are healthy. They are usually loaded with chemicals.
  3. At best, the ratings systems will eliminate the worst of the worst foods. There is no ducking the ratings system if you are a Hostess Twinkie. And if a Twinkie happens to receive a preferential rating, then the credibility of the system is lost.
  4. These systems, if credible, could produce an effect similar to what Los Angeles did 15 years ago when they began to post restaurant cleanliness grades on their front windows. While it may not make much of a difference for the A's, it sure forced the B's, C's, and D's to bring up their grades.
  5. Finally, if there could be a system that could grade based simply upon how "real" a food is, then we'd really have something.
With regard to research data on nutritional quality ratings systems, there is precedence from a recent study in American Journal of Preventive Medicine.

The Overall Nutritional Quality Index (ONQI) algorithm is a nutrient profiling scheme that incorporates more than 30 dietary components, and it aims to rank foods by relative healthfulness. The purpose of the study was to assess whether diets with a higher ONQI score predict lower risk of major chronic disease risk in 62,284 healthy women from the Nurses' Health Study and 42,382 healthy men from Health Professionals Follow-Up Study over a twenty year period.

A total of 20,004 and 13,520 chronic disease events were documented in women and men, respectively. Low ONQI scores were associated with risk of total chronic disease, CVD, diabetes, and all-cause mortality, but not cancer, in both cohorts compared with high scores.

In this study, researchers used the NuVal Nutritional Scoring System, which looks at over 30 factors to determine the score, including the calorie density and Omega-3 content. The NuVal System scores food on a scale of 1-100. The higher the NuVal Score, the better the nutrition. NuVal Scores are displayed directly on shelf price tags, so shoppers can compare overall nutrition the same way they compare prices. Some of the country’s leading grocery chains already feature the NuVal System in their stores including Amigos, Bel Air, Big Y, Brookshire's, City Market, Coborn's, Festival, Food City, HyVee, King Kullen, King Soopers, Lowes Foods, Mariano's, Market Street, Meijer, Metro Market, Nob Hill, Price Chopper, Raley's, Scolari's, Super 1 Foods, Tops Markets, and United.